Five-year outcomes similar for low-risk patients receiving transcatheter, surgical aortic valve replacement

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling stroke at five years compared with those whose valves were replaced through standard open heart surgery, based on new follow-up data from the Evolut Low Risk trial presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) on March 30 in Chicago.